Target Name: USP33
NCBI ID: G23032
Review Report on USP33 Target / Biomarker Content of Review Report on USP33 Target / Biomarker
USP33
Other Name(s): Ubiquitin thioesterase 33 | ubiquitin thiolesterase 33 | ubiquitin thioesterase 33 | deubiquitinating enzyme 33 | USP33 variant 1 | ubiquitin specific peptidase 33 | UBP33_HUMAN | Ubiquitin carboxyl-terminal hydrolase 33 | hVDU1 | VDU1 | VHL-interacting deubiquitinating enzyme 1 | Ubiquitin-specific-processing protease 33 | Ubiquitin thiolesterase 33 | pVHL-interacting deubiquitinating enzyme 1 | Ubiquitin specific protease 33 | ubiquitin-specific-processing protease 33 | Deubiquitinating enzyme 33 | Ubiquitin carboxyl-terminal hydrolase 33 (isoform 1) | Ubiquitin specific peptidase 33, transcript variant 1

USP33 for Ubiquitin-Proteasome Complex (UPC) Mediation of Neurodegenerative Diseases

USP33: A Potential Drug Target and Biomarker for Ubiquitin-Proteasome Complex (UPC) Mediation of Neurodegenerative Diseases

Introduction

The ubiquitin-proteasome complex (UPC) is a complex protein network that plays a crucial role in regulating protein homeostasis, cell signaling, and cellular processes. Ubiquitin, one of the key components of the UPC, is targeted for degradation by the 26S proteasome, a complex protein-protein interaction system that is responsible for breaking down and removing damaged or unnecessary proteins from the cell. However, the UPC also performs other functions, including monitoring the stability of damaged proteins and modulating protein levels to ensure proper cell signaling and cytoskeletal organization. The USP33 protein is one of the key components of the UPC and is involved in these processes.

USP33: A Potential Drug Target

The USP33 protein is a 33 kDa protein that is composed of 116 amino acid residues. It is located at the N-terminus of the ubiquitin molecule and is responsible for the formation of the N-end substructure of ubiquitin. USP33 plays a critical role in the stability and localization of ubiquitin.

Studies have shown that USP33 is involved in the regulation of protein stability and in modulating the activity of the 26S proteasome. USP33 has been shown to interact with the ubiquitin-proteasome complex, including with the 26S proteasome subunit alpha (26S伪) and the ubiquitin- proteasome complex modifier protein (UPM). These interactions may play a role in the regulation of protein stability and the targeted degradation of damaged proteins.

Furthermore, USP33 has been shown to be involved in modulating the level of protein synthesis in the cell. USP33 has been shown to interact with the transcription factor p53 and with the protein Myr1, which is involved in the regulation of gene expression. These interactions may play a role in the regulation of protein synthesis and the targeted degradation of damaged proteins.

USP33: A Potential Biomarker

The USP33 protein is also a potential biomarker for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and other hallmark pathological changes. is involved in the regulation of the stability and localization of ubiquitin, which may be altered in these conditions.

Studies have shown that the levels of USP33 are altered in the brains of individuals with Alzheimer's disease and Parkinson's disease. These conditions are associated with the accumulation of damaged or misfolded proteins, including ubiquitin, in the brain. The USP33 protein has also been shown to be involved in the regulation of protein stability and in modulating the activity of the 26S proteasome, which may be altered in these conditions.

In addition, USP33 has been shown to be involved in the regulation of protein synthesis and the targeted degradation of damaged proteins in the brain. The USP33 protein may be involved in the regulation of the production and degradation of proteins that are involved in neurotransmission and neurotransmitter synthesis, as well as in the regulation of the stability and localization of damaged proteins.

Conclusion

In conclusion, USP33 is a protein that is involved in several critical processes in the cell, including the regulation of protein stability and the targeted degradation of damaged proteins. The USP33 protein is a potential drug target and biomarker for several neurodegenerative diseases, including Alzheimer's disease , Parkinson's disease, and Huntington's disease. Further studies are needed to fully understand the role of USP33 in these conditions and to develop effective treatments.

Protein Name: Ubiquitin Specific Peptidase 33

Functions: Deubiquitinating enzyme involved in various processes such as centrosome duplication, cellular migration and beta-2 adrenergic receptor/ADRB2 recycling. Involved in regulation of centrosome duplication by mediating deubiquitination of CCP110 in S and G2/M phase, leading to stabilize CCP110 during the period which centrioles duplicate and elongate. Involved in cell migration via its interaction with intracellular domain of ROBO1, leading to regulate the Slit signaling. Plays a role in commissural axon guidance cross the ventral midline of the neural tube in a Slit-dependent manner, possibly by mediating the deubiquitination of ROBO1. Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination of beta-arrestins (ARRB1 and ARRB2) and beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, leading to beta-arrestins deubiquitination and disengagement from ADRB2. This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Mediates deubiquitination of both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains

The "USP33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1 | VCPKMT | VCX | VCX2 | VCX3A | VCX3B